REPROCELL Unveils Cutting-Edge Neoantigen Detection Service to Propel Precision Cancer Immunotherapy
Yokohama, Japan, August 20, 2025 REPROCELL is proud to announce the introduction of NeoSight – Neoantigen Detection Service, a state-of-the-art, end-to-end platform designed to empower researchers and clinicians with high-confidence neoantigen data for personalized immuno-oncology applications. This service integrates Next Generation Sequence (NGS) data obtained from whole exome sequencing (WES) of tumor and matched normal…